The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

GLOW Stack

The cosmetic repair triple — skin, hair, and healing combined

C
Animal replicated
Published literature (for this combination)
0human trials0human studies50animal60in vitro

GHK-Cu has human RCT data for topical use but not injectable. The combination has no human trial data of any kind.

Quick take

Each individual component has some evidence basis. The combination has none. GHK-Cu's injectable evidence is zero RCTs — the topical data gets cited to justify the injectable protocol, which is a significant extrapolation. GLOW asks users to trust three separate extrapolations simultaneously.

Components

What each compound contributes — and why it's in the stack.

GHK-Cu
C
Research chemical
50 mg / vial

Collagen synthesis, extracellular matrix remodeling, skin/hair gene expression reset

Full GHK-Cu chapter
BPC-157
C
Research chemical
10 mg / vial

Vascular repair, angiogenesis, gut protection, connective tissue healing

Full BPC-157 chapter
TB-500
C
Research chemical
10 mg / vial

Systemic anti-inflammation, progenitor cell mobilization, actin regulation

Full TB-500 chapter

Documented combination rationale

GLOW extends the Wolverine Stack by adding GHK-Cu's collagen-synthesis and gene-expression effects on top of the BPC-157/TB-500 healing foundation. The rationale is that GHK-Cu modulates extracellular matrix and skin-aging gene programs while BPC-157 and TB-500 drive the underlying vascular and inflammatory repair. The name "GLOW" reflects the cosmetic endpoints the community targets: skin texture, hair quality, and the general appearance-improvement often reported by long-cycle users.

Community-reported protocol

This reflects how this combination is used in practice. It is not a prescribing guide and does not constitute medical advice.

PhaseTimingCompounds & dosesNotes
Vial blend optionAll-in-oneCommunity protocol: combine GHK-Cu + BPC-157 in a single vial reconstituted with BAC water; draw one shot daily. TB-500 stays separate (different dosing frequency).Mixing peptides in one vial is practical but not formally validated for stability. Keep refrigerated, use within 30 days.
Cycle (weeks 1–8)DailyGHK-Cu 1–2 mg SC + BPC-157 250–500 mcg SC + TB-500 2–2.5 mg SC/IM 1–2×/weekAll three run concurrently. Some protocols load GHK-Cu higher (2–3 mg) in the first 2 weeks.
Cycle off (4+ weeks)Monitor serum copper at end of cycle if running GHK-Cu for >8 weeks.Copper accumulation is the primary monitoring target for GLOW given the GHK-Cu component.
Candidate profile

Users seeking combined cosmetic and systemic repair benefits — most commonly women interested in skin and hair improvements who also have or have had connective tissue injuries. Also athletes who want the Wolverine benefits plus a cosmetic layer.

High-risk interactions documented in literature
  • Active malignancy — all three components have angiogenic properties
  • Active cancer or family history of cancer — GHK-Cu adds an extra angiogenic signal
  • Pregnancy or breastfeeding
  • Anyone unwilling to monitor serum copper on extended protocols
Approximate gray-market cost
$140–$350/ month (research-chemical sourcing)

Informational only. Ranges vary significantly by vendor, vial size, and country. No pharmaceutical-grade source exists for most of these compounds; figures are not a buying guide.

Research & community updates

2026-04-12 · 1 month agoNew study

New topical GHK-Cu RCT (Korean, 12-week, double-blind) strengthens the topical evidence base — note this does not validate the injectable route used in GLOW.

Related stacks